About: Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine against Ebola virus elicits a neutralizing antibody response

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine against Ebola virus elicits a neutralizing antibody response Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine against Ebola virus elicits a neutralizing antibody response
Creator	Bukreyev, Alexander Murphy, Brian Yang, Lijuan Collins, Peter Dinapoli, Joshua Samal, Siba
Source	Elsevier; Medline; PMC
abstract	We previously developed a respiratory tract vaccine against Ebola virus (EBOV) based on human parainfluenza virus type 3 (HPIV3), a respiratory paramyxovirus, expressing the EBOV GP envelope protein (HPIV3/GP) from an added gene. Two doses of this vaccine delivered by the intranasal and intratracheal route protected monkeys against intraperitoneal challenge with EBOV; however, concerns exist that the vaccine may have reduced immunogenicity in the adult human population due to pre-existing immunity against HPIV3. Here we developed a new vaccine (NDV/GP) based on Newcastle disease virus (NDV), an avian paramyxovirus that is antigenically distinct from human viral pathogens and is highly attenuated in monkeys. Following one intranasal and intratracheal inoculation of Rhesus monkeys with NDV/GP, titers of EBOV-specific antibodies in respiratory tract secretions and serum samples determined by ELISA, as well as serum EBOV-neutralizing antibodies, were undetectable or low compared to those induced by HPIV3/GP. A second immunization resulted in a substantial boost in serum IgG ELISA titers, yet the titers remained lower than those induced by a second dose of HPIV3/GP. In contrast, the ELISA IgA titers in respiratory tract secretions and, more importantly, the serum EBOV-neutralizing antibody titers were equal to those induced after the second dose of HPIV3/GP. These data suggest that NDV/GP can be effective for immunization against EBOV alone, or in combination with either HPIV3/GP or another vaccine platform in a heterologous prime-boost regimen.
has issue date	2010-12-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2010.10.024
bibo:pmid	21034822
has license	green-oa
sha1sum (hex)	7fdd6624e91af464e7763c7916ba310e518a9a85
schema:url	https://doi.org/10.1016/j.vaccine.2010.10.024
resource representing a document's title	Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine against Ebola virus elicits a neutralizing antibody response
has PubMed Central identifier	PMC3428043
has PubMed identifier	21034822
schema:publication	Vaccine
resource representing a document's body	covid:7fdd6624e91af464e7763c7916ba310e518a9a85#body_text
is schema:about of	named entity 'ELICITS' named entity 'RESPIRATORY TRACT' named entity 'HUMAN' named entity 'Newcastle disease virus' named entity 'candidate' named entity 'intranasal' named entity 'immunization' named entity 'serum' named entity 'Here' named entity 'respiratory tract' named entity 'Respiratory tract' named entity 'ANTIBODY RESPONSE' named entity 'IMMUNIZATION' covid:arg/7fdd6624e91af464e7763c7916ba310e518a9a85 named entity 'VACCINE CANDIDATE' named entity 'PRIME' named entity 'HUMAN' named entity 'BOOST' named entity 'PROTEIN ' named entity 'UNDETECTABLE' named entity 'EITHER' named entity 'AVIAN PARAMYXOVIRUS' named entity 'NEUTRALIZING ANTIBODIES' named entity 'DUE TO' named entity 'THESE' named entity 'IMMUNIZATION' named entity 'IMMUNOGENICITY' named entity 'INTRATRACHEAL' named entity 'EXIST' named entity 'DATA' named entity 'NEUTRALIZING ANTIBODY' named entity 'NEW' named entity 'COMBINATION' named entity 'COMPARED' named entity 'CONCERNS' named entity 'DETERMINED BY' named entity 'HUMAN POPULATION' named entity 'IMMUNITY' named entity 'EBOV GP' named entity 'REGIMEN' named entity 'EQUAL TO' named entity 'PLATFORM' named entity 'HIGHLY' named entity 'DELIVERED' named entity 'VACCINE CANDIDATE' named entity 'IGA' named entity 'EBOLA VIRUS' named entity 'EBOLA VIRUS' named entity 'VECTORED' named entity 'PRIMATES' named entity 'BASED' named entity 'ATTENUATED' named entity 'NEWCASTLE DISEASE VIRUS' named entity 'HERE' named entity 'MONKEYS' named entity 'HUMAN PARAINFLUENZA VIRUS TYPE 3' named entity 'DOSE' named entity 'MAY HAVE' named entity 'INTRATRACHEAL ROUTE' named entity 'ADULT' named entity 'NON-' named entity 'FOLLOWING' named entity 'SERUM' named entity 'SUGGEST' named entity 'PREVIOUSLY' named entity 'CONTRAST' named entity 'DISTINCT FROM' named entity 'HETEROLOGOUS' named entity 'PRE-EXISTING' named entity 'REDUCED' named entity 'ANTIBODY TITERS' named entity 'SECOND' named entity 'RESPIRATORY' named entity 'SECRETIONS' named entity 'ENVELOPE PROTEIN' named entity 'ELISA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software